胰岛素粉样纤维的形成通过三类立体异构体的减少
Beatrice Rosetti1, Slavko Kralj2,3, Erica Scarel1
1Chemical Pharmaceutical Science Department, University of Trieste, 34127 Trieste, Italy. smarchesan@units.it.
Nanoscale
|May 14, 2024
概括
三可以稳定胰岛素配方,防止糖尿病患者的有害动. 研究人员确定了一种特定的三类立体异构体,可以有效抑制胰岛素纤维化,同时保持高细胞兼容性.
科学领域:
- 生物化学 生物化学
- 材料科学 材料科学 材料科学
- 糖尿病学 糖尿病学
背景情况:
- 胰岛素纤维化对糖尿病患者构成风险,导致生物活性丧失和储存,运输和注射期间的不良影响.
- 三胺为稳定胰岛素配方提供了具有成本效益和生物相容性的解决方案.
研究的目的:
- 在实验室中研究八种三类立体异构体在抑制人体胰岛素纤维化的有效性.
- 确定预防胰岛素聚合最有效的三类立体异构体,并了解其作用机制.
主要方法:
- 用光谱,光,显微镜和热量计来评估胰岛素纤维化抑制.
- 使用in silico分析来阐明胰岛素和三抑制剂之间的分子相互作用.
- 进行细胞活/死测定以确认最有效三的细胞相容性.
主要成果:
- 与其他测试的异构体相比,一种特定的三类立体异构体表现出更好的胰岛素纤维化抑制.
- 实验数据证实了这种立体异构体在防止纤维状细胞形成方面的有效性.
- 在模型中确定了胰岛素和三之间的关键相互作用点,解释了观察到的抑制.
结论:
- 一种特定的三类立体异构体在 in vitro 抑制胰岛素纤维化方面非常有效.
- 这种三体具有出色的细胞兼容性,使其成为胰岛素配方的有希望的添加剂.
- 这项研究提供了对三酸抑制胰岛素纤维化的机制的分子见解.
相关概念视频
Insulin: Biosynthesis, Chemistry, and Preparation
374
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
374
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Protein and Protein Structure
79.5K
Proteins are one of the most abundant organic molecules in living systems and have the most diverse range of functions of all macromolecules. Proteins may be structural, regulatory, contractile, or protective. They may serve in transport, storage, or membranes; or they may be toxins or enzymes. Their structures, like their functions, vary greatly. They are all, however, amino acid polymers arranged in a linear sequence.
A protein's shape is critical to its function. For example, an enzyme...
A protein's shape is critical to its function. For example, an enzyme...
79.5K
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Glucagon-like Receptor Agonists
318
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318


